142 related articles for article (PubMed ID: 36518642)
1. 18F-FDG PET/CT scan standardised uptake value (SUV) score for diagnosis, staging and monitoring malignancy in spinal melanotic schwannoma.
Haleem S; Mahmoud MH; Singh Kainth G; Botchu R; Hassan MF
J Surg Case Rep; 2022 Dec; 2022(12):rjac524. PubMed ID: 36518642
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT imaging for aggressive melanotic schwannoma of the L3 spinal root: A case report.
Shen XZ; Wang W; Luo ZY
Medicine (Baltimore); 2021 Feb; 100(8):e24803. PubMed ID: 33663098
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
6. Comparison of histopathology and preoperative 18F-FDG-PET/CT of osteomyelitis aiming for image guided surgery: A preliminary trial.
Takaki M; Takenaka N; Mori K; Harada S; Asahara T; Katoh N; Sakuma H; Saginoya T; Kubota K; Teramoto T; Matsushita T
Injury; 2020 Apr; 51(4):871-877. PubMed ID: 32143858
[TBL] [Abstract][Full Text] [Related]
7. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
8. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
9. An intrathoracic schwannoma case in
Gültekin A; Aydoğmuş Ü; Arifoğlu H; Bir F; Yaylalı O
Hell J Nucl Med; 2020; 23(2):206-208. PubMed ID: 32716413
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Mahajan S; Barker CA; Singh B; Pandit-Taskar N
Nucl Med Commun; 2019 Jul; 40(7):744-751. PubMed ID: 31095044
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal Recurrence of Melanotic Schwannoma on 18F-FDG PET/CT.
OuYang X; Zheng L; Zhang X
Clin Nucl Med; 2021 Dec; 46(12):991-993. PubMed ID: 34560691
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination.
Stangierski A; Woliński K; Czepczyński R; Czarnywojtek A; Lodyga M; Wyszomirska A; Janicka-Jedyńska M; Bączyk M; Ruchała M
PLoS One; 2014; 9(10):e109612. PubMed ID: 25296297
[TBL] [Abstract][Full Text] [Related]
13. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
14. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
15. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
17. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
[TBL] [Abstract][Full Text] [Related]
18. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
19. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the quantitative measurement of 18F-FDG PET/CT and histopathological findings in IgG4-related disease.
Tsuji S; Iwamoto N; Horai Y; Fujikawa K; Fujita Y; Fukui S; Ideguchi R; Michitsuji T; Nishihata S; Okamoto M; Tsuji Y; Endo Y; Shimizu T; Sumiyoshi R; Koga T; Kawashiri SY; Igawa T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kudo T; Kawakami A
Clin Exp Rheumatol; 2021; 39(6):1338-1344. PubMed ID: 33506750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
